Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Down 11.8% in April

Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) was the recipient of a large decrease in short interest in April. As of April 30th, there was short interest totalling 3,800,000 shares, a decrease of 11.8% from the April 15th total of 4,310,000 shares. Based on an average daily volume of 596,800 shares, the days-to-cover ratio is […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Blackrock ,United Kingdom General ,Brian Druker ,Kate Haviland ,Nicholasb Lydon ,Stifel Nicolaus ,Chris Varma ,Christina Rossi ,Metlife Investment Management ,Nasdaq ,Blueprint Medicines Company Profile ,Us Bancorp ,Needham Company ,Blackrock Inc ,Blueprint Medicines Co ,Securities Exchange Commission ,Raymond James Associates ,Blueprint Medicines Corp ,Blueprint Medicines ,Get Rating ,Exchange Commission ,Life Investment Management ,Alexis Borisy ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Stocks ,Options ,Put ,Call ,